Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research
Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines
4 affiliations
- 1Institute of Pharmacology , Medical University of Vienna , Vienna , ;
- 2Department of Special Anaesthesia and Pain Therapy , Medical University of Vienna , Vienna , ;
- 3Diagnostic and Research Institute of Pathology , Medical University Graz , Graz , ;
- 4Karl Landsteiner Institute for Lung Research and Pulmonary Oncology , Department of Respiratory and Critical Care Medicine , Hospital Floridsdorf , Vienna ,
Related
- Bioactive compounds and antioxidant activity of Arbutus fruits from the black sea region
- Isolation, in vitro acetylcholinesterase inhibitory activity, molecular docking, and in silico ADME analysis of compounds from Cadaba farinosa roots
- Sigma‐1 Receptor‐Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models
- A quantitative screening strategy based on activity-content ratio for prioritizing bioactive compounds in medicinal plants
- Could corona-plasma treatment impact the antioxidant activity of phenolic compounds incorporated into gelatin coating applied onto PLA commercial films?
BibTeX
@article{stickler2026activity,
title = {{Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines}},
author = {Sandra Stickler and Marie-Therese Eggerstorfer and Maximilian Rieche and Lukas Weigl and Martin Hohenegger and Karl Kashofer and Maximilian J. Hochmair and Gerhard Hamilton},
journal = {Translational Lung Cancer Research},
year = {2026},
month = aug,
url = {https://europepmc.org/article/PMC/PMC13657876},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines
AU - Sandra Stickler
AU - Marie-Therese Eggerstorfer
AU - Maximilian Rieche
AU - Lukas Weigl
AU - Martin Hohenegger
AU - Karl Kashofer
AU - Maximilian J. Hochmair
AU - Gerhard Hamilton
PY - 2026
DA - 2026/08/21
JO - Translational Lung Cancer Research
UR - https://europepmc.org/article/PMC/PMC13657876
SN - 2218-6751
ER -